After finishing at $79.42 in the prior trading day, Reata Pharmaceuticals Inc. (NASDAQ: RETA) closed at $79.22, down -0.25%. In other words, the price has decreased by -$0.20 from its previous closing price. On the day, 723432 shares were traded. RETA stock price reached its highest trading level at $80.91 during the session, while it also had its lowest trading level at $78.40.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Our goal is to gain a better understanding of RETA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.10 and its Current Ratio is at 6.10.
Upgrades & Downgrades
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 16 when Meyer Colin John sold 625 shares for $80.94 per share. The transaction valued at 50,590 led to the insider holds 78,373 shares of the business.
Soni Manmeet Singh sold 625 shares of RETA for $50,584 on May 16. The COO, CFO and President now owns 116,172 shares after completing the transaction at $80.93 per share. On May 16, another insider, WORTLEY MICHAEL D, who serves as the Chief Legal Officer of the company, sold 417 shares for $80.99 each. As a result, the insider received 33,773 and left with 46,781 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RETA now has a Market Capitalization of 3.21B and an Enterprise Value of 2.95B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2013.24. Its current Enterprise Value per Revenue stands at 1.97k whereas that against EBITDA is -9.50.
Stock Price History:
Over the past 52 weeks, RETA has reached a high of $106.69, while it has fallen to a 52-week low of $18.47. The 50-Day Moving Average of the stock is 92.61, while the 200-Day Moving Average is calculated to be 50.72.
The stock has traded on average 1.45M shares per day over the past 3-months and 1.32M shares per day over the last 10 days, according to various share statistics. A total of 36.95M shares are outstanding, with a floating share count of 30.57M. Insiders hold about 3.83% of the company’s shares, while institutions hold 89.30% stake in the company. Shares short for RETA as of Apr 27, 2023 were 4.79M with a Short Ratio of 4.79M, compared to 5.04M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 12.77% and a Short% of Float of 19.57%.
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of -$2.84 for the current quarter, with a high estimate of -$2.47 and a low estimate of -$3.39, while EPS last year was -$2.02. The consensus estimate for the next quarter is -$2.44, with high estimates of -$1.91 and low estimates of -$3.07.
Analysts are recommending an EPS of between -$8.57 and -$12.15 for the fiscal current year, implying an average EPS of -$10.28. EPS for the following year is -$4.33, with 7 analysts recommending between -$1.94 and -$8.86.
For the next quarter, 7 analysts are estimating revenue of $18.21M, an increase of 3,272.20% over than the figure of $1.00% in the same quarter last year. There is a high estimate of $31.81M for the next quarter, whereas the lowest estimate is $5.53M.
A total of 10 analysts have provided revenue estimates for RETA’s current fiscal year. The highest revenue estimate was $94.65M, while the lowest revenue estimate was $20.6M, resulting in an average revenue estimate of $52.07M. In the same quarter a year ago, actual revenue was $2.22M, up 2,249.70% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $313.79M in the next fiscal year. The high estimate is $411.52M and the low estimate is $164.43M. The average revenue growth estimate for next year is up 502.60% from the average revenue estimate for this year.